Chirality and pharmacokinetics: An area of neglected dimensionality?

Drug Metabolism and Drug Interactions

Volumn 22, Issue 2-3, 2007, Pages 79-112

  Hutt, Andrew J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drug chirality; Factors influencing stereoselective drug disposition; Pharmacokinetic parameters; Racemic drugs

Indexed keywords

AMPICILLIN; BUPIVACAINE; CARVEDILOL; CEFALEXIN; CEPHALOSPORIN; DISOPYRAMIDE; DOBUTAMINE; DOPA; ETHAMBUTOL; ETODOLAC; HEXOBARBITAL; IFOSFAMIDE; INDACRINONE; KETAMINE; KETOROLAC; METHOTREXATE; METHYLPHENOBARBITAL; METOPROLOL; MEXILETINE; NITRENDIPINE; PRENYLAMINE; PROPRANOLOL; REBOXETINE; SALBUTAMOL; SOPROMIDINE; SOTALOL; TALINOLOL; TERODILINE; THIOPENTAL; UNINDEXED DRUG;

CHIRALITY; CONFERENCE PAPER; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; KIDNEY CLEARANCE; PHARMACOGENETICS; STEREOCHEMISTRY; STEREOISOMERISM;

EID: 34547689154     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2007.22.2-3.79     Document Type: Conference Paper

References (101)

1. Ariëns EJ, Wuis EW, Veringa EJ. Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochem Pharmacol 1988; 37: 9-18.
2. Bojarski J, Aboul-Enein HY, Ghanem A. What's new in chromatographic enantioseparations. Curr Anal Chem 2005; 1: 59-77.
3. Cox GB, ed. Preparative Enantioselective Chromatography. Oxford: Blackwell, 2005.
4. Francotte E, Lindner W, eds. Chirality in Drug Research. Weinheim: Wiley-VCH, 2006.
5. Maier NM, Franco P, Lindner W. Separation of enantiomers: needs, challenges, perspectives. J Chromatogr A 2001; 906: 3-33.
6. Nelson TD, Welch CJ, Rosen JD, et al. Effective use of preparative chiral HPLC in a preclinical drug synthesis. Chirality 2004; 16: 609-613.
7. Grabowski EJJ. Enantiopure drug synthesis: from methyldopa to imipenem to efavirenz. Chirality 2005; 17: S249-S259.
8. Shah RR, Midgley JM, Branch SK. Stereochemical origin of some clinically significant drug safety concerns: lessons for future drug development. Adverse Drug React Toxicol Rev 1998; 17: 145-190.
9. nd Ed. Weinheim: Wiley-VCH, 2001; 319-342.
10. Holmstedt B. The use of enantiomers in biological studies: an historical review. In: Holmstedt B, Frank H, Testa B, eds. Chirality and Biological Activity. New York: Alan R Liss, 1990; 1-14.
11. Cushny AR. Biological Relations of Optically Isomeric Substances. London: Bailliere, Tindall and Cox, 1926.
12. Mason SF. Molecular optical activity and the chiral discriminations. Cambridge: Cambridge University Press, 1982; 220-225.
13. Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action V. Molecular dissymmetry and physiological activity. Biochem J 1933; 27: 1257-1266.
14. Ogston AG. Interpretation of experiments on metabolic processes using isotopic tracer elements. Nature 1948; 162: 963.
15. Sokolov VI, Zefirov NS. Enantioselectivity in two-point binding: rocking tetrahedron model. Dokl Akad Nauk SSSR 1991; 319: 1382-1383.
16. Sugiyama K, Trager WF. Prochiral selectivity and intramolecular isotope effects in the cytochrome P-450 catalyzed co-hydroxylation of cumene. Biochemistry 1986; 25: 7336-7343.
17. 3] methoxychlor in rat liver microsomes. Biochem Pharmacol 1987; 36: 3751-3756.
18. Mesecar AD, Koshland DE. A new model for protein stereospecificity. Nature 2000; 403: 614-615.
19. Bentley R. Diastereoisomerism, contact points, and chiral selectivity: a four point saga. Arch Biochem Biophys 2003; 414: 1-12.
20. Topiol S. A general criterion for molecular recognition: implications for chiral interactions. Chirality 1989; 1: 69-79.
21. Topiol S, Sabio M. Interactions between eight centres are required for chiral recognition. J Am Chem Soc 1989; 111: 4109-4110.
22. Lehmann PAF, Rodrigues de Miranda JF, Ariëns EJ. Stereoselectivity and affinity in molecular pharmacology. In: Jucker E, ed. Progress in Drug Research, Vol. 20. Basel: Birkhäuser Verlag, 1976; 101-142.
23. Doyle FP, Fosker GR, Naylor JHC, Smith H. Derivatives of 6-aminopenicillanic acid. Part I α-aminobenzylpenicillin and some related compounds. J Chem Soc 1962: 1440-1444.
24. Wade DN, Mearick PT, Morris JL. Active transport of L-dopa in the intestine. Nature 1972; 242: 463-465.
25. Hendel J, Brodthagen H. Enterohepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. Eur J Clin Pharmacol 1984; 26: 103-107.
26. Itoh T, Ono K, Koido K-I, Li Y-H, Yamada H. Stereselectivity of the folate transporter in rabbit small intestine: studies with amethopterin enantiomers. Chirality 2001; 13: 164-169.
27. Tamai I, Ling H-Y, Timbul S-M, Nishikido J, Tsuji A. Stereospecific absorption and degradation of cephalexin. J Pharm Pharmacol 1988; 40: 320-324.
28. Wetterich H, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P. Evidence for intestinal secretion as additional clearance pathway of talinolol enantiomers: concentration and dose dependent absorption in vitro and in vivo. Pharm Res 1996; 13: 514-522.
29. Zschiesche M, Lemma GL, Klebingat K-J, et al. Stereoselective disposition of talinolol in man. J Pharm Sci 2002; 91: 303-311.
30. 1-acid glycoprotein and albumin. Clin Pharmacol Ther 1983; 34: 718-723.
31. Giacomini KM, Nelson WL, Pershe RA, Valdivieso L, Turner-Tamiyasu K, Blaschke TF. In vivo interaction of the enantiomers of disopyramide in human subjects. J Pharmacokin Biopharm 1986; 14: 335-355.
32. Hanada K, Akimoto S, Mitsui, K, Mihara K, Ogata H. Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding. Pharm Res 1998; 15: 1250-1256.
33. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids - a novel route with pharmacological consequences. J Pharm Pharmacol 1983; 35: 693-704.
34. Caldwell J, Hutt AJ, Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 1988; 37: 105-114.
35. Williams K, Day R, Knihinicki R, Duffield A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 1986; 35: 3403-3405.
36. Sallustio BC, Meffin PJ, Knights KM. The stereospecific incorporation of fenoprofen into rat hepatocyte and adipocyte triacylglycerols. Biochem Pharmacol 1988; 37: 1919-1923.
37. Johnson JL, Brater DC, Hall SD. Formation of "hybrid" glycerolipids in normal volunteers. Clin Pharmacol Ther 1995; 57: 213.
38. Van Bree JBMM, Heijligers-Feijen CD, De Boer AG, Danhof M, Breimer DD. Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. Pharm Res 1991; 8: 259-262.
39. Bertilsson L, Otani K, Dahl M-L, Nordin C, Aberg-Wistedt A. Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patients. Pharmacol Toxicol 1991; 68: 100-103.
40. Walle T, Webb JG, Bagwell EE, Walle UK, Daniell HB, Gaffhey TE. Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 1988; 37: 115-124.
41. Wainer IW, Chen J, Ducharme F, et al. Stereochemical aspects of metabolism and tissue distribution. In: Crommelin DJA, Midha KK, Nagai T, eds. Topics in Pharmaceutical Sciences 1993. Stuttgart: Medpharm Scientific, 1994; 223-246.
42. Jenner P, Testa B. The influence of stereochemical factors on drug disposition. Drug Metab Rev 1973; 3: 117-184.
43. Low LK, Castagnoli N. Enantioselectivity in drug metabolism. In: Clarke FH, ed. Annual Reports in Medicinal Chemistry, Vol. 13. New York: Academic Press, 1978; 304-315.
44. Gietl Y, Spahn H, Knauf H, Mutschler E. Single and multiple-dose pharmacokinetics of (R)-(-)- and (5)-(+)-prenylamine in man. Eur J Clin Pharmacol 1990; 38: 587-593.
45. Ofari-Adjei D, Ericsson O, Lindstrom B, Hermansson J, Adjepon-Yamoah K, Sjoqvist F. Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine. Ther Drug Monit 1986; 8: 457-461.
46. Le Corre P, Gibassier D, Sado P, Le Verge R. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans. Drug Metab Dispos 1988; 16: 858-864.
47. Notterman DA, Drayer DE, Metakis L, Reidenberg MM. Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 1986; 40; 511-517.
48. Okazaki O, Kurata T, Hakusui H, Tachizawa H. Species-related stereoselective disposition of ofloxacin in the rat, dog and monkey. Xenobiotica 1992; 22: 439-450.
49. Kamizono A, Inotsume N, Fukushima S, Nakano M, Okamoto Y. Inhibitory effects of procainamide and probenecid on renal excretion of sultopride enantiomers in rats. J Pharm Sci 1993; 82: 1259-1261.
50. Levy RH, Boddy AV. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991; 8: 551-556.
51. Ariëns EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin. Pharmacol 1984; 26: 663-668.
52. Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA. Stereoselective drug disposition: potential for misinterpretation of drug disposition data. Br J Clin Pharmacol 1988; 26: 771-780.
53. Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert FA, Antonalli T. Amplification of cortical serotonin release; a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000; 39: 1974-1983.
54. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006; 28: 689-706.
55. Dingles DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006; 22: 159-167.
56. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39: 30-40.
57. Wong YN, King P, Simcoe D, et al. Open label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999; 39: 281-288.
58. Gorman SH. Determination of the d- and 1-enantiomers of modafinil in human plasma utilizing liquid-liquid extraction and high-performance liquid chromatography. J Chromatogr B 1999; 730: 1-7.
59. Hirshkowitz M, Black JE, Wesnes K, Niebler G, Arora S, Roth T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Resp Med 2007; 101: 616-627.
60. Sisenwine SF, Tio CO, Hadley FV, Liu A-L, Kimmel HB, Ruelius HW. Species-related differences in the stereoselective glucuronidation of oxazepam. Drug Metab Dispos 1982; 10: 605-608.
61. Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995; 7: 44-52.
62. Fabro S, Smith RL, Williams RT. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 1967; 215: 269.
63. Reist M, Carrupt P-A, Francotte E, Testa B. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol 1998; 11: 1521-1528.
64. Tetlow VA, Merrill J. Rapid determination of amphetamine stereoisomer ratios in urine by gas chromatography-mass spectroscopy. Ann Clin Biochem 1996; 33: 50-54.
65. Fitzgerald RL, Ramos JM, Bogema SC, Poklis A. Resolution of methamphetamine stereoisomers in urine drug testing: urinary excretion of R-(-)-methamphetamine enantiomer data. J Anal Toxicol 1988; 18: 49-51.
66. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ. Stereospecific analysis and enantiomeric disposition of 3,4- methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 1999; 45: 1058-1069.
67. Gillespie L, Oates JA, Cront JR, Sjoerdsma A. Clinical and chemical studies with α-methyldopa in patients with hypertension. Circulation 1962; 25: 281-291.
68. Kubota H, Numami K, Hayashi K, et al. Studies on angiotensin converting enzyme inhibitor VI. Synthesis and angiotensin converting enzyme inhibitory activities of the dicarboxylic acid derivative of imidapril and its diastereoisomers. Chem Pharm Bull 1992; 40: 1619-1622.
69. Carter RB, Dykstra LA. Quantitative analysis of the interaction between the agonist and antagonist isomers of picenadol (LY 150720) on electric shock titration in the squirrel monkey. Eur J Pharmacol 1985; 106: 469-476.
70. Schunack W, Schwarz S, Gerhard G, Buyuktimkin S, Elz S. Chiral agonists of histamine. In: Ganellin CR, Schwartz JC, eds. Frontiers in Histamine Research. Oxford: Pergamon, 1985; 39-46.
71. Vlasses PH, Irvin JD, Huber PB, et al. Pharmacology of enantiomers and (-)-p-shy; OH metabolite of indacrinone. Clin Pharmacol Ther 1981; 29: 798-807.
72. Tobert JA, Cirillo VJ, Hitzenberger G, et al. Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio. Clin Pharmacol Ther 1981; 29: 344-350.
73. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998; 87: 1186-1193.
74. Blessington B. Ethambutol and tuberculosis, a neglected and confused chiral puzzle. In: Aboul-Enein HY, Wainer IW, eds. The Impact of Stereochemistry on Drug Development and Use. New York: Wiley-Interscience, 1997; 235-261.
75. Ruffolo RR. Chirality in α- and β-adrenoceptor agonists and antagonists. Tetrahedron 1991; 47: 9953-9980.
76. Tucker GT, Lennard MS. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990; 45: 309-329.
77. Eichelbaum M, Gross AS. Stereochemical aspects of drug action and disposition. In: Testa B, Meyer UA, eds. Advances in Drug Research, Vol. 28. London: Academic Press, 1996; 1-64.
78. Hutt AJ. Drug chirality: stereoselectivity in the action and disposition of anaesthetic agents. In: Adams AP, Cashman JN, Grounds RM, eds. Recent Advances in Anaesthesia and Intensive Care, Vol. 22. London: Greenwich Medical Media, 2003; 31-64.
79. th Ed. Boca Raton, FL: CRC Press, 2006; 117-183.
80. Cashman JR, Park SB, Yany Z-C, et al. Chemical, enzymatic and human enantioselective S-oxygenation of cimetidine. Drug Metab Dispos 1993; 21: 587-597.
81. Kuzel RA, Bhasir SK, Oldham HG, et al. Investigations into the chirality of the metabolic sulfoxidation of cimetidine. Chirality 1994; 6: 607-614.
82. Poupaert JH, Cavalier R, Claasen MH, Dumont PA. Absolute configuration of the major metabolite of 5,5-diphenylhydantoin, 5-(4′-hydroxyphenyl)-5- phenylhydantoin. J Med Chem 1975; 18: 1268-1271.
83. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P450 2C9 in the aetiology of (S)-warfarin drug interactions. Chem Res Toxicol 1992; 5: 54-59.
84. Äbelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidorf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966-972.
85. Bartels MJ, Smith FA. Stereochemical inversion of haloxyfop in the Fischer 344 rat. Drug Metab Dispos 1989; 17: 286-291.
86. Echizen H, Vogelgesang B, Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther 1985; 38: 71-76.
87. Soons PA, Breimer DD. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. Br J Clin Pharmacol 1991; 32: 11-16.
88. Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996; 41: 35-40.
89. Ward JK, Dow J, Dallow N, Eynott P, Milleri S, Ventresca GP. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man - no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 2000; 49: 15-22.
90. Avgerinos A, Noormohammadi A, Hutt AJ. Disposition of ibuprofen enantiomers following the oral administration of a novel controlled release formulation to healthy volunteers. Int J Pharmaceut 1991; 68: 97-103.
91. Karim A, Piergies A. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Clin Pharmacol Ther 1995; 58: 174-184.
92. Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther 1990; 253: 1042-1048.
93. Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. Br J Clin Pharmacol 1991; 32: 735-739.
94. Tan SC, Patel BK, Jackson SHD, Swift CG, Hutt AJ. Influence of age on the enantioselective disposition of ibuprofen in healthy volunteers. Br J Clin Pharmacol 2003; 55: 579-587.
95. Patel BK, Jackson SHD, Swift CG, Hutt AJ. Disposition of flubiprofen in man: influence of stereochemistry and age. Xenobiotica 2003; 33: 1043-1057.
96. Chandler MMH, Scott SR, Blouin RA. Age associated stereoselective alterations in hexobarbital metabolism. Clin Pharmacol Ther 1988; 43: 436-441.
97. Li G, Treiber G, Maier K, Walker S, Klotz U. Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. Clin Pharmacokin 1993; 25: 154-163.
98. Hooper WD, Qing MS. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin Pharmacol Ther 1990; 48: 633-640.
99. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolisers. Clin Pharmacol Ther 1983; 34: 732-737.
100. Fjordside L, Jeppesen U, Eap CB, Poweel K, Baumann P, Brosen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 1999; 9: 55-60.
101. Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther 1992; 51: 495-500.